High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3634-3640

  Tam, Andrew S ^a   Foley, Julie F ^b   Devereux, Theodora R ^b   Maronpot, Robert R ^b   Massey, Thomas E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; AMINO ACID; DNA; PROTEIN P53;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DELETION MUTANT; EXON; FEMALE; GENE MUTATION; LUNG ADENOMA; LUNG CARCINOMA; LUNG TUMOR; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADENOMA; AFLATOXIN B1; ANIMALS; CARCINOMA; CROSSES, GENETIC; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; GENES, P53; LUNG NEOPLASMS; MICE; MICE, INBRED A; MICE, INBRED C3H; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0033179379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. 1. J. Natl. Cancer Inst., 40: 1195-1197, 1968.
2. Stoner, G. D. Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp. Lung Res., 17: 405-423, 1991.
3. 1 carcinogenicity. Proc. Soc. Exp. Biol. Med., 208: 213-227, 1995.
4. Dickens, F., Jones, H. E. H., and Waynforth, H. B. Oral, subcutaneous and intratracheal administration of carcinogenic lactones and related substances: the intratracheal administration of cigarette tar in the rat. Br. J. Cancer, 20: 134-144, 1966.
5. 1: patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis. Drag Metab. Rev., 13: 581-602, 1982.
6. 1-DNA adducts in cultured mammalian tracheal epithelium. Cancer Res., 50: 4918-4922, 1990.
7. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., and Devilee, P. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
8. Weinberg, R. A. Tumor suppressor genes. Science (Washington DC), 254: 1138-1146, 1991.
9. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
10. Caron, D. F., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer, 4: 1-15, 1992.
11. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1: 45-49, 1992.
12. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., and Vogelstein, B. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
13. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
14. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
15. Lane, D. P. Cancer. p53, guardian of the genome. Nature (Lond. ), 358: 15-16, 1992.
16. Soini, Y., Chia, S. C., Bennett, W. P., Groopman, J. D., Wang, J. S., DeBenedetti, V. M., Cawley, H., Welsh, J. A., Hansen, C., Bergasa, N. V., Jones, E. A., DiBisceglie, A. M., Trivers, G. E., Sandoval, C. A., Calderon, I. E., Munoz, E. L., and Harris, C. C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis (Lond.), 17: 1007-1012, 1996.
17. Aguilar, F., Harris, C. C., Sun, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington DC), 264: 1317-1319, 1994.
18. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., and Harris, C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond.), 350: 427-428, 1991.
19. Bressac, B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature (Lond.), 350: 429-431, 1991.
20. Ozturk, M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338: 1356-1359, 1991.
21. Scorsone, K. A., Zhou, Y-Z., Butel, J. S., and Slagle, B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res., 52: 1635-1638, 1992.
22. Ghebranious, N., Knoll, B. J., Wu, H., Lozano, G., and Sell, S. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol. Carcinogen., 13: 104-111, 1995.
23. Dragani, T. A., Manenti, G., and Pierotti, M. A. Genetics of murine lung tumors. Adv. Cancer Res., 67: 83-112, 1995.
24. Goodrow, T. L., Storer, R. D., Leander, K. R., Prahalada, S. R., van Zwieten, M. J., and Bradley, M. O. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/ direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinogen., 5: 9-15, 1992.
25. Chen, B., Liu, L., Castonguay, A., Maronpot, R. R., Anderson, M. W., and You, M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors. Carcinogenesis (Lond.), 14: 1603-1608, 1993.
26. 6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol. Carcinogen., 8: 177-185, 1993.
27. Li, E. E., Heflich, R. H., Bucci, T. J., Manjanatha, M. G., Blaydes, B. S., and Delclos, K. B. Relationships of DNA adduct formation, K-ras activating mutations and tumorigenic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis (Lond.), 15: 1377-1385, 1994.
28. Hegi, M. E., Soderkvist, P., Foley, J. F., Schoonhoven, R., Swenberg, J. A., Kari, F., Maronpot, R. R., Anderson, M. W., and Wiseman, R. W. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803-810, 1993.
29. Horio, Y., Chen, A., Rice, P., Roth, J. A., Malkinson, A. M., and Schrump, D. S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol. Carcinogen., 17: 217-223, 1996.
30. 1-induced lung tumors from AC3F1(A/J X C3H/HeJ) mice. Carcinogenesis (Lond.), 17: 1735-1740, 1996.
31. Foley, J. F., Anderson, M. W., Stoner, G. D., Gaul, B. W., Hardisty, J. F., and Maronpot, R. R. Proliferative lesions of the mouse lung: progression studies in strain A mice. Exp. Lung Res., 17: 157-168, 1991.
32. Bonner, R. F., Emmert-Buck, M., Cole, K., Pohida, T., Chuaqui, R., Goldstein, S., and Liotta, L. A. Laser capture microdissection: molecular analysis of tissue. Science (Washington DC), 278: 1481-1483, 1997.
33. Sekido, Y., Fong, K. M., and Minna, J. D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta, 1378: F21-F59, 1998.
34. Hussain, S. P., and Harris, C. C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res., 58: 4023-4037, 1998.
35. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., and Levine, A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ., 1: 571-580, 1990.
36. Li, Z. H., Zheng, J., Weiss, L. M., and Shibata, D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol., 144: 303-309, 1994.
37. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
38. Bodner, S. M., Minna, J. D., Jensen, S. M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., Gazdar, A. F., and Linnoila, R. I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
39. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
40. Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science (Washington DC), 274: 430-432, 1996.
41. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
42. Knudson, A. G. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol., 122: 135-140, 1996.
43. Chakravarty, G., Redkar, A., and Mittra, I. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br. J. Cancer, 74: 1181-1187, 1996.
44. Fujino, M., Dosaka-Akita, H., Kato, M., Kinoshita, I., Akie, K., and Kawakami, Y. Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am. J. Clin. Pathol., 104: 319-324, 1995.
45. Chung, F-L., Wang, M., Rivenson, A., Iatropoulos, M. J., Reinhardt, J. C., Pittman, B., Ho, C-T., and Amin, S. G. Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res., 58: 4096-4101, 1998.
46. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
47. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
48. Qian, G. S., Yu, M. C., Ross, R., Yuan, J. M., Gao, Y. T., Wogan, G. N., and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, P. R. C. Cancer Epidemiol. Biomark. Prev., 3: 3-11, 1994.
49. Ross, R. K., Yuan, J. M., Yu, M. C., Wogan, G. N., Qian, G. S., Tu, J. T., Groopman, J. D., Gao, Y. T., and Henderson, B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943-946, 1992.
50. Ross, R. K., Yu, M. C., Henderson, B. E., Yuan, J. M., Qian, G. S., Tu, J. T., Gao, Y. T., Wogan, G. N., and Groopman, J. D. Aflatoxin biomarkers. Lancet, 340: 119, 1992.
51. Ghebranious, N., and Sell, S. Hepatitis B injury, male gender, aflaloxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology, 27: 383-391, 1998.
52. 1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res., 53: 9-11, 1993.
53. 1 in nonhuman primates. Cancer Res., 52: 1044-1046, 1992.
54. 1. Prog. Clin. Biol. Res., 376: 203-222, 1992.
55. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
56. Bogler, O., Huang, H. J., Kleihues, P., and Cavenee, W. K. The p53 gene and its role in human brain tumors. Glia, 15: 308-327, 1995.
57. Biggs, P. J., Warren, W., Venitt, S., and Stratton, M. R. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis, 8: 275-283, 1993.
58. 1 adducts. Oncogene, 17: 3007-3014, 1998.
59. Trukhanova, L. S., Hong, H. H., Sills, R. C., Bowser, A. D., Gaul, B., Boorman, G. A., Turusov, V. S., Devereux, T. R., and Dixon, D. Predominant p53 G→A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethyl-hydrazine. Toxicol. Pathol., 26: 367-374, 1998.